(Q24186393)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

0 references

1 reference

title

Interventions for hirsutism (excluding laser and photoepilation therapy alone) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Esther J van Zuuren

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Ben Carter

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Nikolaos Pandis

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

28 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

6 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

CD010334

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Cyproterone acetate for severe hirsutism:results of a double-blind dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effects of exercise on lipoprotein particles in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The effect of metformin on hirsutism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Finasteride cream in hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Lack of effect of spironolactone on hair shaft diameter in hirsute females

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of Sequential Cyproterone Acetate/Estrogen Versus Spironolactone/Oral Contraceptive in the Treatment of Hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Oral contraceptives containing desogestrel in the maintenance of the remission of hirsutism: Monthly versus bimonthly treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Dexamethasone and spironolactone in the treatment of non-tumorous hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effect of daily and alternate day low dose prednisone on serum cortisol and adrenal androgens in hirsute women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Altering hirsutism through ovulation induction in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The effects of benzodiazepines on hormones in women with idiopathic hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

[Ovarian suppression with Diane 35/50]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Abnormalities in the serum insulin-like growth factor-1 axis in women with hyperandrogenism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Steroid Therapy in Hirsutism and Virilism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

A comparison between finasteride, flutamide, and finasteride plus flutamide combination in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Medical and technical issues in office electrolysis and thermolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effects of a holistic yoga program on endocrine parameters in adolescents with polycystic ovarian syndrome: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Metformin and pioglitazone in polycystic ovarian syndrome: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Androgen excess in women: experience with over 1000 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Psychological morbidity in women referred for treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Medical treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

An overview of unwanted female hair

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

How to diagnose and treat medically women with excessive hair

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Hirsutism: Diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

How to formulate research recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Comprehensive clinical management of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Reanalyzing the modified Ferriman-Gallwey score: is there a simpler method for assessing the extent of hirsutism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

"It is always on my mind": women's experiences of their bodies when living with hirsutism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

"We feel rejected": experiences of women with hirsutism consulting physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Diagnosis and management of hirsutism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Ethinylestradiol/Chlormadinone acetate: dermatological benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Laser and photoepilation for unwanted hair growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Laser and intense pulsed light hair removal technologies: from professional to home use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Estimating the mean and variance from the median, range, and the size of a sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

A systematic review of commonly used medical treatments for hirsutism in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Management of unwanted hair in females

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Women living with facial hair: the psychological and behavioral burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Laser treatment improves quality of life of hirsute females

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Familial study of hirsutism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Medical treatment of hirsutism in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Lifestyle changes in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

21 January 2018

Methods of hair removal

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The Hirsute woman: challenges in evaluation and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Androgens and hair growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Electrolysis: observations from 13 years and 140,000 hours of experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Clinical practice. Hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Meta-analysis of hair removal laser trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The clinical evaluation of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Quality of life of hirsute women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

A system for rating the stability and strength of medical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Cyproterone acetate for hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Interventions for female pattern hair loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Interventions for hirsutism excluding laser and photoepilation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Long-Term Efficacy and Tolerability of Flutamide Combined with Oral Contraception in Moderate to Severe Hirsutism: A 12-Month, Double-Blind, Parallel Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome—a double-blind randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Intermittent Low-Dose Finasteride Administration Is Effective for Treatment of Hirsutism in Adolescent Girls: A Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

Recurrence rate of hirsutism after 3 different antiandrogen therapies

21 January 2018

1 reference

12 December 2020

Comparison of finasteride and flutamide in the treatment of idiopathic hirsutism

1 reference

12 December 2020

Comparison of finasteride versus flutamide in the treatment of hirsutism

1 reference

12 December 2020

Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women

1 reference

12 December 2020

Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial

1 reference

12 December 2020

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

12 December 2020

A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles.

1 reference

12 December 2020

A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism

1 reference

12 December 2020

Spironolactone as a single agent for long-term therapy of hirsute patients

1 reference

12 December 2020

Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile

1 reference

12 December 2020

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

1 reference

12 December 2020

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study

1 reference

12 December 2020

Eflornithine cream for facial hair reduction

1 reference

12 December 2020

The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenic women

1 reference

12 December 2020

[Treatment of hirsutism with spironolactone and with spironolactone plus dexamethasone]

1 reference

12 December 2020

A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism

1 reference

12 December 2020

Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism.

1 reference

12 December 2020

Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial

1 reference

12 December 2020

Troglitazone use in polycystic ovary syndrome

1 reference

12 December 2020

The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea

1 reference

12 December 2020

The effectiveness of two oral contraceptives in suppressing plasma androstenedione, testosterone, LH, and FSH, and in stimulating plasma testosterone-binding capacity in hirsute women

1 reference

12 December 2020

The evaluation and management of hirsutism*1

1 reference

12 December 2020

The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue

1 reference

12 December 2020

Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism

1 reference

12 December 2020

The treatment of virilizing syndromes. Comparative clinical studies of 2 antiandrogen-active gestagens (cyproterone acetate, megestrol acetate

1 reference

12 December 2020

Anti-androgenic steroid cyproterone acetate. Clinical pharmacology and therapeutic use in hirsutism and acne

1 reference

12 December 2020

Antihirsutism activity of Fennel (fruits of Foeniculum vulgare) extract. A double-blind placebo controlled study

1 reference

12 December 2020

Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol

1 reference

12 December 2020

Therapy of androgenization symptoms: double blind study of an antiandrogen preparation (SH B 209 AB) against neogynon (author's transl)

1 reference

12 December 2020

'Hirsutism': a psychological analysis.

1 reference

12 December 2020

Treatment of moderate and severe hirsutism with a gonadotrophin-releasing hormone agonist

1 reference

12 December 2020

Metformin, an efficacious drug in the treatment of polycystic ovary syndrome

1 reference

12 December 2020

Effectiveness of flutamide alone or combined with oral contraceptives in the treatment of hirsutism in women

1 reference

12 December 2020

The Development and Evaluation of An Ovulation Inhibitor (Diane®) Containing An Antiandrogen

1 reference

12 December 2020

Eflornithine: evidence of efficacy

1 reference

12 December 2020

Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study

1 reference

12 December 2020

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial

1 reference

12 December 2020

Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism

1 reference

12 December 2020

Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial

1 reference

12 December 2020

Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial

1 reference

12 December 2020

Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome

1 reference

12 December 2020

Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome

1 reference

12 December 2020

Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome

1 reference

12 December 2020

Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism

1 reference

12 December 2020

Long-term follow up of women with laparoscopic ovarian diathermy for women with clomiphene-resistant polycystic ovarian syndrome

1 reference

12 December 2020

Effects of ketoconazole in hirsute women

1 reference

12 December 2020

Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17β-estradiol

1 reference

12 December 2020

Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives

1 reference

12 December 2020

Ultrasound-guided transvaginal ovarian needle drilling (UTND) for treatment of polycystic ovary syndrome: a randomized controlled trial

1 reference

12 December 2020

Combination of cyproterone acetate and natural estrogens in the treatment of hirsutism

1 reference

12 December 2020

Double-blind, randomized, placebo-controlled trial of a cream containing the Stryphnodendron adstringens (Martius) Coville bark extract for suppressing terminal hair growth

1 reference

12 December 2020

Management of hirsutism

1 reference

12 December 2020

1 reference

12 December 2020

Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial

1 reference

12 December 2020

European Consensus on the evaluation of women presenting with excessive hair growth

1 reference

12 December 2020

Meta-analyses involving cross-over trials: methodological issues

1 reference

12 December 2020

Desogestrel+ethinylestradiol versus levonorgestrel+ethinylestradiol. Which one has better affect on acne, hirsutism, and weight change.

1 reference

12 December 2020

Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens

1 reference

12 December 2020

Current standards in the diagnostics and therapy of hair diseases - hair consultation.

1 reference

12 December 2020

Hormonal treatment effectivity in hyperandrogenic syndrome

1 reference

12 December 2020

Effect of ketoconazole on plasma sex hormones, lipids, lipoproteins, and apolipoproteins in hyperandrogenic women

1 reference

12 December 2020

Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.

1 reference

12 December 2020

Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism

1 reference

12 December 2020

Factors affecting the degree of hirsutism in patients with polycystic ovary syndrome

1 reference

12 December 2020

Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study

1 reference

12 December 2020

Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation

1 reference

12 December 2020

A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism

1 reference

12 December 2020

[Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]

1 reference

12 December 2020

1 reference

12 December 2020

Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue

1 reference

12 December 2020

Possible efficacy of Lavender and Tea tree oils in the treatment of young women affected by mild idiopathic hirsutism.

1 reference

12 December 2020

In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone

1 reference

12 December 2020

The effect of fennel (Foeniculum vulgare) gel 3% in decreasing hair thickness in idiopathic mild to moderate hirsutism, A randomized placebo controlled clinical trial

1 reference

12 December 2020

Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial

1 reference

12 December 2020

Treatment of hirsutism with cimetidine: a prospective randomized controlled trial

1 reference

12 December 2020

The Effect of Flutamide on Ovulation Induction in PCOS Patients

1 reference

12 December 2020

Finasteride for hirsutism: a dose finding study

1 reference

12 December 2020

Cyproterone acetate as initial treatment and maintenance therapy for hirsutism

1 reference

12 December 2020

The treatment of hirsutism: experience with cyproterone acetate and spironolactone

1 reference

12 December 2020

[Hirsutism treated with cyproterone acetate and ethinyl estradiol. Influence on androgens in the serum and urine and on urinary cortisol]

1 reference

12 December 2020

[Hirsutism treated with cyproterone acetate and ethinyl estradiol. Evaluation of the clinical effect]

1 reference

12 December 2020

Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study.

1 reference

12 December 2020

[Efficacy of oral contraceptives on acne. Apropos of a comparative study of Varnoline vs Diane in 69 women with acne]

1 reference

12 December 2020

Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome

1 reference

12 December 2020

Treatment of hirsutism in polycystic ovary syndrome with bromocriptine

1 reference

12 December 2020

Lack of effect of a spironolactone-containing cream on hair growth in hirsute women

1 reference

12 December 2020

Endocrine and clinical effects of spironolactone in female hyperandrogenism

1 reference

12 December 2020

A comparative study of Aldactone and Diane in the treatment of hirsutism

1 reference

12 December 2020

Parenteral and oral cyproterone acetate treatment in severe hirsutism

1 reference

12 December 2020

Therapeutic evaluation of spironolactone in Indian women with hirsutism

1 reference

12 December 2020

The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women**Supported in part by National Institutes of Health grant HD-17519-01A1

1 reference

12 December 2020

A comparative study of the effects of electrical epilation of beard hairs in women with hirsutism by diathermy and by the blend method

1 reference

12 December 2020

The comparative effects of the administration of cortisone, estrogen-progestin, and placebo on the clinical manifestations of the polycystic ovary (Stein-Leventhal) syndrome

1 reference

12 December 2020

Topical aminoglutethimide in hirsutism

1 reference

12 December 2020

Effect of a new hormonal contraceptive (Neo-Eunomin) in females with androgenization symptoms

1 reference

12 December 2020

Clinical trial of cyproterone acetate-ethinyl oestradiol compound on androgen dependent skin disorders

1 reference

12 December 2020

Analysis of the results of treatment of idiopathic hirsutism and hirsutism in patients with polycystic ovary syndrome with androcur (cyproterone acetate)

1 reference

12 December 2020

[Medium-dose oral cyproterone acetate therapy in women with moderate androgenization. Results of a multicenter double-blind study]

1 reference

12 December 2020

[A short clinical trial of cyproterone acetate in the treatment of idiopathic hirsutism]

1 reference

12 December 2020

[Epilation of facial hirsutism in women. A study of the therapeutic effects]

1 reference

12 December 2020

An assessment of (1) cyproterone acetate and (2) ethinyl oestradiol and lynoestrenol (Minilyn) in the treatment of idiopathic hirsutism

1 reference

12 December 2020

Hirsutism: implications, etiology, and management

1 reference

12 December 2020

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women

1 reference

12 December 2020

Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism

1 reference

12 December 2020

Gonadotropin-releasing hormone agonist (GnRH-A) in hirsutism

1 reference

12 December 2020

Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.

1 reference

12 December 2020

Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism

1 reference

12 December 2020

[Acceptability, tolerance and quality of life impact of cyproterone acetate treatment in female hirsutism. Comparison of 2 protocols in combination with oral or transdermal estradiol]

1 reference

12 December 2020

A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women

1 reference

12 December 2020

17 beta-Estradiol: oral or parenteral administration in hyperandrogenic women? Metabolic tolerance in association with cyproterone acetate.

1 reference

12 December 2020

Efficacy of flutamide versus spironolactone

1 reference

12 December 2020

Treatment of polycystic ovarian disease during adolescence with ethinylestradiol/cyproterone acetate versus a D-Tr-6-LHRH analog

1 reference

12 December 2020

Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment of hirsutism

1 reference

12 December 2020

Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.

1 reference

12 December 2020

Comparison of the efficacy of spironolactone**Spironolactone (Aldactone; Searle, Chicago, IL). versus flutamide††Flutamide (Eulexin; Schering Plough Laboratories, Heist, Belgium). in the treatment of hirsutism‡‡Presented in part at the 3rd Wo

1 reference

12 December 2020

Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism

1 reference

12 December 2020

Clinical and endocrine effects of flutamide in hyperandrogenic women

1 reference

12 December 2020

Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism

1 reference

12 December 2020

Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial**Supported in part by Schering-Plough, Pointe-Claire, Québec, Canada

1 reference

12 December 2020

Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.

1 reference

12 December 2020

Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism

1 reference

12 December 2020

Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism

1 reference

12 December 2020

Finasteride in the treatment of hirsutism: new therapeutic perspectives

1 reference

12 December 2020

An open randomized comparative study of an oral contraceptive containing ethinyl estradiol and cyproterone acetate with and without the GnRH analogue goserelin in the long-term treatment of hirsutism.

1 reference

12 December 2020

Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-relate

1 reference

12 December 2020

Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission

1 reference

12 December 2020

A comparison between two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism

1 reference

12 December 2020

Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism

1 reference

12 December 2020

[Finasteride and flutamide in the treatment of hirsutism]

1 reference

12 December 2020

Interval estimation for the difference between independent proportions: comparison of eleven methods

1 reference

12 December 2020

The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission

1 reference

12 December 2020

Contraceptive and therapeutic effectiveness of two low-dose ethinylestradiol and cyproterone acetate regimens in the treatment of hirsute patients

1 reference

12 December 2020

Effects on bone mass of two oral contraceptives containing ethinylestradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up

1 reference

12 December 2020

Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism

1 reference

12 December 2020

Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study**Sponsored by the Canadian Fertility Research Association and funded by a grant-in-aid from Berlen Laboratories Limited, Canada.††T

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

7 January 2021

inferred from DOI database lookup

Effects of ketoconazole in hirsute women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010334.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD010334.PUB2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

release_24da5ovalzchrpwtwemqn3rfdy

6 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/24da5ovalzchrpwtwemqn3rfdy

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25918921%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

PubMed publication ID

25918921

1 reference